Skip to main content
BioThera Solutions

Long-form writing on EVs, grounded in the data.

Articles on extracellular vesicle science, characterization standards, and the questions clinicians and partners actually ask. No press-release cadence. No marketing-grade hedging. The published evidence, read carefully, with the limits stated where they sit.

12 pieces, authored by the founding team.

01

Communicating EV science to patients: a plain-language guide for clinicians

Patients now arrive asking about exosome skincare. The science is real, the evidence is early, and the marketing runs ahead of both. Here is how to explain what an extracellular vesicle product can and cannot do, in words a patient can follow.

Frédéric St-Denis-Bissonnette, PhD

02

How to choose a plant-derived exosome (EV) supplier: the questions buyers should ask

More clinics and brands now ask for plant-derived rather than human-derived extracellular vesicles. The category is young, the labels are loose, and two products from the same plant can be very different. Ten questions separate a characterized supplier from a label.

Frédéric St-Denis-Bissonnette, PhD

03

Topical, microneedling or injectable: what sterility and endotoxin testing tell you about an EV (exosome) product

The same vial of extracellular vesicles can be a reasonable cosmetic and an unsafe injectable. What separates them is not the vesicles. It is sterility, endotoxin, and the regulatory class the product was made for.

Frédéric St-Denis-Bissonnette, PhD

04

Freeze-dried extracellular vesicles (exosomes): does lyophilization damage them, and how should they be stored?

Extracellular vesicles can still be present in a vial long after they have stopped doing anything. Storage, not isolation, is where many EV products quietly lose their activity. Freeze-drying can fix that, if it is done and checked properly.

Frédéric St-Denis-Bissonnette, PhD

05

What extracellular vesicles actually are, and why "exosome" is the wrong word for most products

EVs are not a category of skincare ingredient. They are a class of biological particles defined by how they are made. Three biogenesis routes, three subpopulations, and a vocabulary problem that has shaped the entire commercial market.

Frédéric St-Denis-Bissonnette, PhD

06

Plant-derived versus mammalian extracellular vesicles, compared honestly

Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map.

Frédéric St-Denis-Bissonnette, PhD

07

Cross-kingdom EV signalling: what the evidence supports, and what it does not

Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once.

Frédéric St-Denis-Bissonnette, PhD

08

Extracellular vesicles versus PRP for skin applications

PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point.

Frédéric St-Denis-Bissonnette, PhD

09

The biomolecular corona, and why isolation method changes what an EV product actually is

Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved.

Frédéric St-Denis-Bissonnette, PhD

10

How to evaluate an EV or exosome product before stocking it

Five criteria: source, particle concentration, Certificate of Analysis, isolation method, storage and stability. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it.

Frédéric St-Denis-Bissonnette, PhD

11

Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation

Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature.

Frédéric St-Denis-Bissonnette, PhD

12

Post-procedure EV protocols: what we can say, and what is still under evaluation

Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome.

Frédéric St-Denis-Bissonnette, PhD

Working with us on the science.

Clinical evaluators, dermatology partners, and qualified researchers can request the EV SELECT GUIDE or open a direct conversation with the team.

BioThera Solutions

A fully integrated extracellular vesicle company, from research and intellectual property to manufacturing, with a process designed to scale. Extracellular vesicles (EVs/exosomes) are among biology's most promising delivery systems, and we are building the infrastructure the field has been missing.

Ottawa, Ontario, Canada
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 9B4 Canada
Add BioThera Solutions as a preferred source on Google

© 2026 BioThera Solutions Inc. All rights reserved.

For informational purposes only. Nothing on this website is medical advice. BioThera develops and manufactures characterized extracellular vesicles (exosomes) and, for cosmetic applications, licenses its technology exclusively to Vesera™, a skincare company and BioThera subsidiary. Vesera™ products are cosmetics and are not intended to diagnose, treat, cure, or prevent any disease. BioThera does not sell products to consumers, and its work on therapeutic applications is research only.